evlampiyacyxybyw.blogspot.com
The Department of Health’s proposed regulations related to marketinyg activities by pharmaceutical and medical device manufacturers will creatw an unquestionably restrictive environment forthese companies. the administration wisely opted to exclude from the requirementse disclosure of legitimate payments related toclinical trials. A vocal minority has sincre raiseda stink, suggestingg that the state health officials caved to This is ridiculous. The administrationj has simply done the right Recent data from showeed thatin 2005, biopharmaceutical-related companiezs were responsible for almost 55,000 jobs in the state.
The university’as also projected that 15,000 new jobs in the biopharmaceuticapl industry will be generated in Massachusettseby 2014. Lawmakers showed greatt determination and vision in championin the recently enacted lifesciences initiative. Thesed efforts could have been jeopardized if not for the actionws of the Department of Our state officials took crucial steps to ensure that ongoinh clinical research conducted in partnership between localk physiciansand scientists, academic medical centerw and life sciences companies is not threatene d by overly restrictive disclosure requirements.
It is the righft decision for thepublic health, for this unique and dynamifc life sciences sector, and for the near-termj prospects of our local economy. Kelly Thompson Clark Presidenttand CEO,
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment